Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19

[1]  Benjamin S. Glicksberg,et al.  Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19 , 2020, Journal of the American College of Cardiology.

[2]  C. Plymen,et al.  The effect of concomitant COVID‐19 infection on outcomes in patients hospitalized with heart failure , 2020, ESC heart failure.

[3]  S. Solomon,et al.  Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium , 2020, European journal of heart failure.

[4]  S. Solomon,et al.  Severe COVID-19 Is a Microvascular Disease , 2020, Circulation.

[5]  S. Farhadian,et al.  Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.

[6]  P. Libby,et al.  COVID-19 is, in the end, an endothelial disease , 2020, European heart journal.

[7]  R. Bhopal,et al.  Sex differential in COVID-19 mortality varies markedly by age , 2020, The Lancet.

[8]  D. Gallagher,et al.  Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection , 2020, Annals of Internal Medicine.

[9]  D. Lewis,et al.  COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives , 2020, Nature Reviews Cardiology.

[10]  Simon A. Jones,et al.  Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. , 2020, JAMA.

[11]  S. Del Prato,et al.  COVID-19 in people with diabetes: understanding the reasons for worse outcomes , 2020, The Lancet Diabetes & Endocrinology.

[12]  C. O'connor,et al.  Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19 , 2020, JACC. Heart failure.

[13]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[14]  N. Reza,et al.  Considerations for Heart Failure Care During the COVID-19 Pandemic , 2020, JACC: Heart Failure.

[15]  D. Kerr,et al.  COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.

[16]  P. Ponikowski,et al.  Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors , 2020, European heart journal.

[17]  Thomas J Oxley,et al.  Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young , 2020, The New England journal of medicine.

[18]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[19]  Jeffrey Ferranti,et al.  Telehealth transformation: COVID-19 and the rise of virtual care , 2020, J. Am. Medical Informatics Assoc..

[20]  C. Yancy,et al.  COVID-19 and African Americans. , 2020, JAMA.

[21]  Marc A Pfeffer,et al.  Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[22]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[23]  Sanjiv J. Shah,et al.  Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. , 2020, JACC. Heart failure.

[24]  A. Dunning,et al.  The burden of non‐cardiac comorbidities and association with clinical outcomes in an acute heart failure trial – insights from ASCEND‐HF , 2020, European journal of heart failure.

[25]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[26]  D. Brodie,et al.  The Variety of Cardiovascular Presentations of COVID-19 , 2020, Circulation.

[27]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[28]  C. O'connor,et al.  Specificity of administrative coding for older adults with acute heart failure hospitalizations. , 2020, American heart journal.

[29]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[30]  Deepak L. Bhatt,et al.  Effect of Influenza on Outcomes in Patients With Heart Failure. , 2019, JACC. Heart failure.

[31]  S. Solomon,et al.  Influenza vaccination: a one-shot deal to reduce cardiovascular events , 2016, European heart journal.

[32]  D. Mann.  Innate immunity and the failing heart: the cytokine hypothesis revisited. , 2015, Circulation research.

[33]  Robert J Mentz,et al.  Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[34]  Vicki Freedman,et al.  Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. , 2004, Health services research.

[35]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[36]  Osaka Hiroki,et al.  HFpEF(heart failure with preserved ejection fraction)における心臓内幹細胞移植の治療効果と機序解明 , 2017 .